FDA Gives Priority Review for What Could be the First Therapy for Eosinophilic Esophagitis
source: pixabay.com

FDA Gives Priority Review for What Could be the First Therapy for Eosinophilic Esophagitis

Takeda has just announced that their application to the the FDA for their eosinophilic esophagitis (EoE)  investigative therapy has received Priority Review. This therapy is called budesonide oral suspension or…

Continue Reading FDA Gives Priority Review for What Could be the First Therapy for Eosinophilic Esophagitis
The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
source: pixabay.com

The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment

According to a story from GlobeNewswire, the medication dupilumab (marketed as Dupixent®) has demonstrated potential efficacy in a phase 3 clinical trial as a treatment for eosinophilic esophagitis, a rare…

Continue Reading The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
Eosinophilic Esophagitis Patients at High Risk of Relapse After Stopping Treatment, Study Says
jarmoluk / Pixabay

Eosinophilic Esophagitis Patients at High Risk of Relapse After Stopping Treatment, Study Says

According to a story from Healio, the results of a randomized trial suggest that patients with eosinophilic esophagitis are likely to experience rapid relapse if they stop treatment. This was…

Continue Reading Eosinophilic Esophagitis Patients at High Risk of Relapse After Stopping Treatment, Study Says
The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis
Pexels / Pixabay

The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis

According to a story from Check Orphan, the biopharmaceutical company AstraZeneca recently announced that its drug benralizumab (marketed as Fasenra) has earned Orphan Drug designation from the US Food and…

Continue Reading The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis